» Articles » PMID: 35079628

Biophysical Targeting of High-risk Cerebral Aneurysms

Overview
Date 2022 Jan 26
PMID 35079628
Authors
Affiliations
Soon will be listed here.
Abstract

Localized delivery of diagnostic/therapeutic agents to cerebral aneurysms, lesions in brain arteries, may offer a new treatment paradigm. Since aneurysm rupture leading to subarachnoid hemorrhage is a devastating medical emergency with high mortality, the ability to noninvasively diagnose high-risk aneurysms is of paramount importance. Moreover, treatment of unruptured aneurysms with invasive surgery or minimally invasive neurointerventional surgery poses relatively high risk and there is presently no medical treatment of aneurysms. Here, leveraging the endogenous biophysical properties of brain aneurysms, we develop particulate carriers designed to localize in aneurysm low-shear flows as well as to adhere to a diseased vessel wall, a known characteristic of high-risk aneurysms. We first show, in an in vitro model, flow guided targeting to aneurysms using micron-sized (2 μm) particles, that exhibited enhanced targeting (>7 folds) to the aneurysm cavity while smaller nanoparticles (200 nm) showed no preferable accumulation. We then functionalize the microparticles with glycoprotein VI (GPVI), the main platelet receptor for collagen under low-medium shear, and study their targeting in an in vitro reconstructed patient-specific aneurysm that contained a disrupted endothelium at the cavity. Results in this model showed that GPVI microparticles localize at the injured aneurysm an order of magnitude (>9 folds) more than control particles. Finally, effective targeting to aneurysm sites was also demonstrated in an in vivo rabbit aneurysm model with a disrupted endothelium. Altogether, the presented biophysical strategy for targeted delivery may offer new treatment opportunities for cerebral aneurysms.

Citing Articles

Cerebral Aneurysm: Filling the Gap Between Pathophysiology and Nanocarriers.

Toader C, Radoi M, Covlea C, Covache-Busuioc R, Ilie M, Glavan L Int J Mol Sci. 2024; 25(22).

PMID: 39595942 PMC: 11593836. DOI: 10.3390/ijms252211874.


The Biofabrication of Diseased Artery In Vitro Models.

Pan C, Gao Q, Kim B, Han Y, Gao G Micromachines (Basel). 2022; 13(2).

PMID: 35208450 PMC: 8874977. DOI: 10.3390/mi13020326.


Biophysical targeting of high-risk cerebral aneurysms.

Epshtein M, Levi M, Kraitem A, Zidan H, King R, Gawaz M Bioeng Transl Med. 2022; 7(1):e10251.

PMID: 35079628 PMC: 8780020. DOI: 10.1002/btm2.10251.


Characterization of GPVI- or GPVI-CD39-Coated Nanoparticles and Their Impact on In Vitro Thrombus Formation.

Nestele J, Rohlfing A, Dicenta V, Bild A, Eissler D, Emschermann F Int J Mol Sci. 2022; 23(1).

PMID: 35008437 PMC: 8744670. DOI: 10.3390/ijms23010011.

References
1.
Khoury M, Epshtein M, Zidan H, Zukerman H, Korin N . Mapping deposition of particles in reconstructed models of human arteries. J Control Release. 2019; 318:78-85. DOI: 10.1016/j.jconrel.2019.12.004. View

2.
Hoh B, Hosaka K, Downes D, Nowicki K, Wilmer E, Velat G . Stromal cell-derived factor-1 promoted angiogenesis and inflammatory cell infiltration in aneurysm walls. J Neurosurg. 2013; 120(1):73-86. PMC: 3877706. DOI: 10.3171/2013.9.JNS122074. View

3.
Brinjikji W, Murad M, Lanzino G, Cloft H, Kallmes D . Endovascular treatment of intracranial aneurysms with flow diverters: a meta-analysis. Stroke. 2013; 44(2):442-7. DOI: 10.1161/STROKEAHA.112.678151. View

4.
Villablanca J, Duckwiler G, Jahan R, Tateshima S, Martin N, Frazee J . Natural history of asymptomatic unruptured cerebral aneurysms evaluated at CT angiography: growth and rupture incidence and correlation with epidemiologic risk factors. Radiology. 2013; 269(1):258-65. DOI: 10.1148/radiol.13121188. View

5.
Levi M, Epshtein M, Castor T, Gawaz M, Korin N . Glycoprotein VI (GPVI)-functionalized nanoparticles targeting arterial injury sites under physiological flow. Nanomedicine. 2020; 29:102274. DOI: 10.1016/j.nano.2020.102274. View